RECOFIB A unique commercially viable recombinant manufacturing platform for human fibrinogen (rhFib) & thrombin (rhThr
- Coordinator
- Fibriant BV, Netherlands
- Runs
- 1 April 2022 to 31 December 2023
- Status
- Ended early
- EU funding
- €2.5m
- Total cost
- €4.5m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190183175
What the project is doing
In the project's own words, from its summary on CORDIS.
We have developed the RECOFIB platform, a market first recombinant production platform for human fibrinogen (rhFib) & thrombin (rhThr). Using Chinese Hamster Ovary Cells (CHO) expression technology & patented upstream purification processes, we are the first producer of fully intact & functional recombinant fibrinogen and active thrombin at commercially acceptable cost ending reliance on blood plasma. Our RECOFIB platform can produce individual fibrinogen variants whose specific functional properties can now be fully harnessed-a breakthrough discovery.
From these individual variants, we can develop customized products for [1] bioactive topical hemostats to stop excessive bleeding during surgery; [2] medical implant coating reducing antibiotic resistance of MRSA bacterial biofilms and [3] supply of rhFib variants & rhThr as OEM products. Additional benefits of our rhFib variants compared to plasma fibrinogen include more stability, 10–100X higher purity, and improved safety profile.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Fibriant BV | Leiden | Netherlands | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI